Cargando…
D‐dimer testing in clinical practice in the era of COVID‐19
D‐dimer is a fragment of crosslinked fibrin resulting from plasmin cleavage of fibrin clots and hence an indirect biomarker of the hemostatic system activation. Early in the coronavirus disease 2019 (COVID‐19) pandemic, several studies described coagulation disorders in affected patients, including...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133433/ https://www.ncbi.nlm.nih.gov/pubmed/35664536 http://dx.doi.org/10.1002/rth2.12730 |
_version_ | 1784713566562025472 |
---|---|
author | Auditeau, Claire Khider, Lina Planquette, Benjamin Sanchez, Olivier Smadja, David M. Gendron, Nicolas |
author_facet | Auditeau, Claire Khider, Lina Planquette, Benjamin Sanchez, Olivier Smadja, David M. Gendron, Nicolas |
author_sort | Auditeau, Claire |
collection | PubMed |
description | D‐dimer is a fragment of crosslinked fibrin resulting from plasmin cleavage of fibrin clots and hence an indirect biomarker of the hemostatic system activation. Early in the coronavirus disease 2019 (COVID‐19) pandemic, several studies described coagulation disorders in affected patients, including high D‐dimer levels. Consequently, D‐dimer has been widely used in not‐yet‐approved indications. Ruling out pulmonary embolism and deep vein thrombosis in patients with low or intermediate clinical suspicion is the main application of D‐dimer. D‐dimer is also used to estimate the risk of venous thromboembolism recurrence and is included in the ISTH algorithm for the diagnosis of disseminated intravascular coagulation. Finally, numerous studies identified high D‐dimer levels as a biomarker of poor prognosis in hospitalized patients with COVID‐19. This report focuses on validated applications of D‐dimer testing in patients with and without COVID‐19. |
format | Online Article Text |
id | pubmed-9133433 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91334332022-06-04 D‐dimer testing in clinical practice in the era of COVID‐19 Auditeau, Claire Khider, Lina Planquette, Benjamin Sanchez, Olivier Smadja, David M. Gendron, Nicolas Res Pract Thromb Haemost Forum D‐dimer is a fragment of crosslinked fibrin resulting from plasmin cleavage of fibrin clots and hence an indirect biomarker of the hemostatic system activation. Early in the coronavirus disease 2019 (COVID‐19) pandemic, several studies described coagulation disorders in affected patients, including high D‐dimer levels. Consequently, D‐dimer has been widely used in not‐yet‐approved indications. Ruling out pulmonary embolism and deep vein thrombosis in patients with low or intermediate clinical suspicion is the main application of D‐dimer. D‐dimer is also used to estimate the risk of venous thromboembolism recurrence and is included in the ISTH algorithm for the diagnosis of disseminated intravascular coagulation. Finally, numerous studies identified high D‐dimer levels as a biomarker of poor prognosis in hospitalized patients with COVID‐19. This report focuses on validated applications of D‐dimer testing in patients with and without COVID‐19. John Wiley and Sons Inc. 2022-05-25 /pmc/articles/PMC9133433/ /pubmed/35664536 http://dx.doi.org/10.1002/rth2.12730 Text en © 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH). https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Forum Auditeau, Claire Khider, Lina Planquette, Benjamin Sanchez, Olivier Smadja, David M. Gendron, Nicolas D‐dimer testing in clinical practice in the era of COVID‐19 |
title | D‐dimer testing in clinical practice in the era of COVID‐19 |
title_full | D‐dimer testing in clinical practice in the era of COVID‐19 |
title_fullStr | D‐dimer testing in clinical practice in the era of COVID‐19 |
title_full_unstemmed | D‐dimer testing in clinical practice in the era of COVID‐19 |
title_short | D‐dimer testing in clinical practice in the era of COVID‐19 |
title_sort | d‐dimer testing in clinical practice in the era of covid‐19 |
topic | Forum |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133433/ https://www.ncbi.nlm.nih.gov/pubmed/35664536 http://dx.doi.org/10.1002/rth2.12730 |
work_keys_str_mv | AT auditeauclaire ddimertestinginclinicalpracticeintheeraofcovid19 AT khiderlina ddimertestinginclinicalpracticeintheeraofcovid19 AT planquettebenjamin ddimertestinginclinicalpracticeintheeraofcovid19 AT sanchezolivier ddimertestinginclinicalpracticeintheeraofcovid19 AT smadjadavidm ddimertestinginclinicalpracticeintheeraofcovid19 AT gendronnicolas ddimertestinginclinicalpracticeintheeraofcovid19 |